Mentions
Extended reach
Total likes
Video views
AI synopsis
Multiple mentions cite the trial results, emphasizing weight loss percentages and comparing with existing treatments, such as 'a pill that can help you lose 20%' and 'significant weight reduction over 72 weeks.' The tone is enthusiastic and cautiously optimistic, underscoring the drug's potential to revolutionize obesity management by providing an oral alternative to injections, as seen in phrases like 'fewer hospital visits' and 'broad access.' This consistent focus on effectiveness and accessibility supports the conclusion that this discussion has high agreement, interest, and impact.
Most mentions are highly positive, emphasizing the trial results, potential impact, and drug efficacy.
Mentions highlight excitement and curiosity about the new oral medication, its benefits, and implications for obesity treatment.
While many mentions show detailed discussion of study data, some are more superficial or just share headlines, limiting deeper analysis.
The mentions collectively reflect significant attention from the medical and general community, suggesting high potential influence on treatment landscape.
Scientists reveal pill that helps you lose 20% body weight. For years, powerful obesity medications have meant injections. But now, scientists say a daily pill may offer similar results – and greater access. Researchers have published results from a massive international trial of orforglipron, an oral drug that mimics GLP-1 hormones. The study followed more than 3,100 adults with obesity but not diabetes, across nine countries, for 72 weeks. Patients took either a placebo or one of three daily doses of orforglipron, alongside diet and activity. The results were striking. At the highest dose, patients lost an average of 11% of their body weight. More than half lost at least 10%, over one third lost 15% or more, and nearly one in five shed at least 20%. For comparison, the placebo group averaged just a 2% drop. Beyond weight, the pill improved waist size, blood pressure, triglycerides,
Big randomized trial of a GLP- pill (vs placebo) achieves significant weight loss www.nejm.org/doi/full/10....
Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) https://t.co/avDbBYKZDr #Endocrinology https://t.co/xFALCq2XqV
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial https://t.co/ElGCZnxmHB
Here are three Original Articles from September that made big news: 1️⃣ Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 trial) https://t.co/X22BVSx58v ??????? ?????????: Daily weight loss pill can help cut body weight by a fifth, trial shows (The Guardian) https://t.co/AScH38a41x Lilly’s Obesity Pill Will Have Far-Reaching Effect, Doctors Say (Bloomberg) https://t.co/4NItt24Plv
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 receptor agonists. #Cardiology #MedTwitter #CardioTwitter #HeartHealth #Healthcare @CMichaelGibson @DLBHATTMD @DrMarthaGulati @kamleshkhunti @hvanspall @NEJM @AndrewJSauer @ankeetbhatt @Hragy @AnastasiaSMihai @biljana_parapid https://t.co/5t36x0jVj6
Orforglipron, an oral small-molecule GLP-1 receptor agonist, was tested over 72 weeks in a phase 3 trial involving 1613 adults with obesity and type 2 diabetes, showing a mean bodyweight reduction of -5.1%. Participants…
Orforglipron, an oral small-molecule GLP-1 receptor agonist, was tested over 72 weeks in a phase 3 trial involving 1613 adults with obesity and type 2 diabetes, showing a mean bodyweight reduction of 5.1%. This…
The FDA approved the first true Ozempic pill, forglipron, sold as Foundayo. This video explains how it differs from Ozempic, the science behind developing an oral GLP-1 drug, and explores the true effectiveness and…
Orforglipron, an oral small-molecule GLP-1 receptor agonist, was tested over 72 weeks in a phase 3 trial involving 1613 adults with obesity and type 2 diabetes, showing a mean bodyweight reduction of -5.1%. Participants…
Orforglipron, an oral small-molecule GLP-1 receptor agonist, was tested over 72 weeks in a phase 3 trial involving 1613 adults with obesity and type 2 diabetes, showing a mean bodyweight reduction of -5.1%. The trial…
Foundayo just changed EVERYTHING about weight loss. No needles. No fasting rules. No water restrictions. Just one pill, once a day — any time of day. In a clinical trial, participants lost an average of 27 pounds with…
Is the new weight loss drug Foundayo right for you? Dr. Howard explains the clinical trial data, side effects, and who this medication may benefit, helping you make an informed decision based on evidence rather than…
Orforglipron, an oral small-molecule GLP-1 receptor agonist, was tested over 72 weeks in a phase 3 trial involving 1613 adults with obesity and type 2 diabetes, showing a mean bodyweight reduction of -5.1%. The…
Emagrecer com uma caneta e depois manter o resultado com um comprimido: onde termina a expectativa e começa a evidência? Nesta análise, discutimos o orforglipron, uma molécula não peptídica aprovada pela FDA, que ativa…
Ozempic. Wegovy. Mounjaro. Zepbound. They're everywhere — but almost nobody explains what they actually do at the level of the biology. This video breaks down how GLP-1 and dual GIP/GLP-1 medications work, their…
I know the news came out on April 1st, but this is not a prank. A new non-peptide GLP-1 tablet called Foundayo has been approved. It bypasses stomach acid, allowing administration without fasting. While not as effective…
¿Puede un GLP-1 oral lograr una pérdida de peso clínicamente relevante sin necesidad de inyecciones? Este análisis del ensayo ATTAIN-1 evalúa la eficacia, dosis, efectos secundarios y posibles aplicaciones del…
Orforglipron is now FDA-approved as Foundayo, making it one of the first serious oral small-molecule GLP-1 weight loss medications. In this video, we analyze how it works, compare it to injectable GLP-1 agonists like…
This issue reviews recent research including the phase 3 trial of orforglipron, an oral GLP-1 receptor agonist for obesity and type 2 diabetes, showing significant weight loss. It also covers real-world validation of…
In this video, I review the recent approval of Foundayo (orforglipron) and compare its efficacy and safety data with Wegovy (semaglutide). I discuss pivotal clinical trial results and share insights on which medication…
This issue will review recent findings on Orforglipron, an oral GLP-1 receptor agonist, demonstrating significant bodyweight reduction in adults with obesity and type 2 diabetes over 72 weeks, highlighting its potential…
What to expect from weight loss with GLP-1 medications is a complex topic discussed in this video. It covers how these drugs work, recent study findings on each, and how to set realistic expectations to prevent…
Since weekly injections for obesity treatment may soon change, oral solutions like orforglipron offer new possibilities. Clinical trials show significant weight loss over 72 weeks, with potential for broader impact…
Orforglipron, an oral small-molecule GLP-1 receptor agonist, was tested over 72 weeks in a phase 3 trial involving 1613 adults with obesity and type 2 diabetes, showing a mean bodyweight reduction of -5.1%. The study…
There are now two FDA-approved GLP-1 pills for weight loss, and they are not the same drug. Dr. Clete Barrick analyzes the chemistry, dosing, effectiveness, side effects, costs, and suitable patient profiles for each…
Full appraisal: https://youtu.be/ufr94GJgnOw ATTAIN-2 tested once-daily oral orforglipron, a non-peptide small-molecule GLP-1 receptor agonist, over 72 weeks in adults with obesity or overweight and type 2 diabetes. The…
This study summarizes phase 3 trial results of oral orforglipron, a GLP-1 receptor agonist, in adults with obesity and type 2 diabetes. Over 72 weeks, it significantly reduced weight and improved blood sugar, offering a…
Orforglipron, an oral small-molecule GLP-1 receptor agonist, was tested over 72 weeks in a phase 3 trial involving 1613 adults with obesity and type 2 diabetes. The study showed a mean weight loss of 5.1%, highlighting…
New medicine for weight loss, Orforglipron, offers an effective alternative to injectable treatments. Tested over 72 weeks, it resulted in an average loss of 5.1% body weight in adults with obesity and type 2 diabetes…
No vídeo de hoje apresento e discuto um artigo científico recente sobre o Orforglipron, um agonista oral do receptor de GLP-1 destacado como uma nova alternativa para tratar obesidade e diabetes tipo 2. Os resultados do…
@DrChavezDiaz No pues prefiero orfoglipron... https://t.co/oX9BPTqNu4 y me quiero las molestias del viaje al más allá... ?
【肥満治療：経口非ペプチドGLP-1受容体作動薬orforglipron】 タイトル：Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment（ATTAIN-1） ✅️【出典】 New England Journal of Medicine, 2025 ✅️【研究デザイン】 第3相・国際多施設共同・二重盲検・無作為化・プラセボ対照試験。 ✅️【対象】 糖尿病のない成人肥満患者3,127例。 ✅️【介入・比較】 健康的な食事と身体活動に加え、経口orforglipron 6mg、12mg、36mgまたはプラセボを1日1回、72週間投与。 ✅️【主要評価項目】 72週時点におけるベースラインからの体重変化率。 ✅️【主要結果】 平均体重変化率は6mg群−7.5％、12mg群−8.4％、36mg群−11.2％、プラセボ群−2.1％で、すべての用量がプラセボより有意に大きな減量と関連しました。36mg群では、体重が10％以上減少した患者54.6％、15％以上36.0％、20％以上18.4％で、プラセボ群ではそれぞれ12.9％、5.9％、2.8％でした。 腹囲、収縮期血圧、中性脂肪、非HDLコレステロールも改善しました。有害事象による中止はorforglipron群5.3～10.3％、プラセボ群2.7％で、主な有害事象は軽度～中等度の消化器症状でした。 ✅️【臨床的解釈】 注射を必要としない低分子のGLP-1（glucagon-like peptide-1：食欲や血糖調節に関与する消化管ホルモン）受容体作動薬でも、用量依存的な体重減少が得られる可能性が示されました。注射製剤を希望しない患者の選択肢になり得ます。 ただし、本試験は既存の注射型GLP-1製剤との直接比較ではありません。心血管イベントの抑制、減量の長期維持、投与終了後の体重変化もこの試験だけでは判断できません。 ✅️【限界】 糖尿病のない肥満患者を対象とした72週間の試験で、長期安全性や心血管転帰は評価されていませ
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment https://t.co/F3EewHorca
Ozempic in a Pill. Here's the Catch. https://t.co/s7EJt3ClDE via @YouTube
https://t.co/ama7yRMNGs
https://t.co/EMKsaFrLG8
https://t.co/2DHZCHwxKL
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. There is a lot of interest among patients about this drug. It makes you loose about 11% body weight and could be cheaper then some of the current medication https://t.co/lqLNildrw3
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment https://t.co/9LYvheUUbX
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/si9OEMXjcI
Eli Lilly plans to invest USD3 billion over the next decade to expand its supply chain capacity in China, the US drugmaker said today. The firm will set up a local production and supply network for tablets and capsules and build manufacturing capabilities for orforglipron, an oral small-molecule GLP-1 receptor agonist for treating type 2 diabetes and obesity. @EliLillyandCo
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial - The Lancet https://t.co/pXyxXZZdDS - administered by oral route
HOT TOPIC OF THE WEEK Most viewed paper on BioFingertips: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. This is what healthcare professionals are reading right now. Read it on BioFingertips: https://t.co/w2fEjD0vKT #BioFingertips #HotTopicOfTheWeek #GLP1 #ObesityTreatment #HealthcareProfessionals
For today's journal club, Dr. K C discussed the ??? ??????? ??????? ?? ???????? article “Orforglipron, an Oral Small Molecule GLP 1 Receptor Agonist for Obesity Treatment.” https://t.co/Hz36cwmQee
EvidenceAlerts | Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. https://t.co/Ghr7pWJYrt
EvidenceAlerts | Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. www.evidencealerts.com/Social/Artic...
EvidenceAlerts | Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. www.evidencealerts.com/Social/Artic...
“Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.” Publié ce jour dans @thelancet.com. #MedSky #EndoSky www.thelancet.com/journals/lan...
Orforglipron ATTAIN-2 trial in adults with T2D: Average wt reduction: highest dose (36 mg): -10.5% (~22.9 lbs) vs. -2.2% (placebo). >50% achieved HbA1c ≤6.5% on any dose. DOI: 10.1016/S0140-6736(25)02165-8 #Obesity #Diabetes #T2D #Endocrinology #Orforglipron
[Articles] Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial https://t.co/nWjxMHw4HK
www.nejm.org/doi/full/10.... www.thelancet.com/journals/lan...
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial - The Lancet https://t.co/WBgZgB9CHR
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/U3MIokvSsH
Good news for folk with excess weight and type 2 diabetes - an oral alternative to injectable GLP-1 receptor agonists. Dose response r/ship in weight loss and majority of participants getting below HbA1c of 6.5%. www.sciencedirect.com/science/arti...
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
【RCT】BMI27以上およびHbA1c7–10%の患者へのOrforglipron投与は、プラセボ投与と比較して、ベースラインから72週時点での体重をより減少させた。 #ペ読 https://t.co/awKd4A1HZT
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 receptor agonists. #Cardiology #MedTwitter #CardioTwitter #HeartHealth #Healthcare @CMichaelGibson @DLBHATTMD @DrMarthaGulati @kamleshkhunti @hvanspall @NEJM @AndrewJSauer @ankeetbhatt @Hragy @AnastasiaSMihai @biljana_parapid https://t.co/5t36x0jVj6
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. https://t.co/mgXNdNFFqL
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial - The Lancet https://t.co/qeiVoRpYfR
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial https://t.co/ElGCZnxmHB
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind. Orforglipron, in people with diabetes and obesity shows significant weight loss. https://t.co/mgXNdNFFqL
RT @agingdoc1: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial https://t.co/BkWNPBcty8
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial "We aimed to evaluate orforglipron, an oral small-molecule (non-peptide) GLP-1 receptor agonist, for obesity treatment in adults with type 2 diabetes..." ?Weight loss of 9.6% with daily 36 mg orforglipron https://t.co/w27UmHMIZ4
www.nejm.org/doi/full/10....
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. This new drug is way more effective for dropping pounds, and the best part is it's just a pill you swallow! Read. https://t.co/ggGKN8l1YK
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 receptor agonists. @DrMarthaGulati @hvanspall @AndrewJSauer @kamleshkhunti @ankeetbhatt @Hragy @biljana_parapid @AnastasiaSMihai #Cardiology #MedTwitter #CardioTwitter #HeartHealth #Healthcare https://t.co/5t36x0jVj6
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) https://t.co/avDbBYKZDr #Endocrinology https://t.co/xFALCq2XqV
Oral easy-to-take GLP-1 Agonists are going to transform the market even more than injectables making them broadly adoptable. Implications are immense: Fewer hospital admissions (11% lower for heart failure, 20-24% lower among patients with diabetes for stroke and MI) Less money spent on food and possibly alcohol (5-10% lower grocery spend per user) Lower rates of hypertension, diabetes, high lipids Decreased obesity surgery by 10-15% 12% reduction in all-cause mortality Lower rates of kidney disease patients needing dialysis Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/QIqgGBbUUU (I have no interest in any pharmaceutical company and this will actually decrease the number of patients we get in the ER; it will make life tougher to finance hospitals)
In the ATTAIN-1 phase 3, randomized trial, the use of orforglipron, an oral glucagon-like peptide-1 receptor agonist, led to significant mean body-weight reductions in patients with #obesity, as compared with placebo. Full trial results and Research Summary: nej.md/4n1nSl2 #MedSky #EndoSky
RT @ValleAlfonso: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity ?phase 3, randomized trial, the use of orforglipr…
RT @ValleAlfonso: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity ?phase 3, randomized trial, the use of orforglipr…
RT @ValleAlfonso: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity ?phase 3, randomized trial, the use of orforglipr…
RT @ValleAlfonso: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity ?phase 3, randomized trial, the use of orforglipr…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/zHzwg0rJ3A
RT @ValleAlfonso: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity ?phase 3, randomized trial, the use of orforglipr…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @ValleAlfonso: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity ?phase 3, randomized trial, the use of orforglipr…
RT @ValleAlfonso: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity ?phase 3, randomized trial, the use of orforglipr…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/HrFHV5wO6Q
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @ValleAlfonso: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity ?phase 3, randomized trial, the use of orforglipr…
RT @ValleAlfonso: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity ?phase 3, randomized trial, the use of orforglipr…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity ?phase 3, randomized trial, the use of orforglipron, an oral glucagon-like peptide-1 receptor agonist ?significant mean body-weight ⬇️ in patients with obesity vs placebo: ⬇️ 54.6% of 10% or more ⬇️ 36.0% had a reduction of 15% or more, ⬇️ 18.4% had a reduction of 20% or more, ?12.9%, 5.9%, and 2.8% of the patients, respectively, in the placebo group ? DOI: 10.1056/NEJMdo008238 @NEJM
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
“Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” Publié ce jour dans le @nejm.org. #MedSky #EndoSky www.nejm.org/doi/full/10....
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @agingdoc1: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment https://t.co/ifTueKLWh7
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @VivekSubbiah: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/GNhaj2cf7G this week in @NEJM
RT @VivekSubbiah: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https…
RT @VivekSubbiah: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https…
RT @VivekSubbiah: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https…
RT @agingdoc1: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment https://t.co/ifTueKLWh7
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment https://t.co/ifTueKLWh7
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/SyI4OEeiom
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/R3Ye5VVhAg
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment https://t.co/lqLNildrw3
Here are three Original Articles from September that made big news: 1️⃣ Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 trial) https://t.co/X22BVSx58v ??????? ?????????: Daily weight loss pill can help cut body weight by a fifth, trial shows (The Guardian) https://t.co/AScH38a41x Lilly’s Obesity Pill Will Have Far-Reaching Effect, Doctors Say (Bloomberg) https://t.co/4NItt24Plv
Scientists reveal pill that helps you lose 20% body weight. For years, powerful obesity medications have meant injections. But now, scientists say a daily pill may offer similar results – and greater access. Researchers have published results from a massive international trial of orforglipron, an oral drug that mimics GLP-1 hormones. The study followed more than 3,100 adults with obesity but not diabetes, across nine countries, for 72 weeks. Patients took either a placebo or one of three daily doses of orforglipron, alongside diet and activity. The results were striking. At the highest dose, patients lost an average of 11% of their body weight. More than half lost at least 10%, over one third lost 15% or more, and nearly one in five shed at least 20%. For comparison, the placebo group averaged just a 2% drop. Beyond weight, the pill improved waist size, blood pressure, triglycerides,
In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 receptor agonists. #NEJM www.nejm.org/doi/full/10....
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/zHzwg0rJ3A
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment #MedTwitter
RT @medpedshosp: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https:…
RT @medpedshosp: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https:…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/rWSnCVEQRh
RT @medpedshosp: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https:…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/PK5E4J7YMg
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment www.nejm.org/doi/10.1056/... #hvhebron #endo
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment https://t.co/Fd2WEsNMxw #hvhebron #endo
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment #science #publication #research #publications https://t.co/VK62hraqjm
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
La democratización y uso temprano de los GLP1 pudiese llegar con los NUEVOS GLP1 orales https://t.co/aqxJPwS90c Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity AND https://t.co/ZsK10EeNkQ Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment #EASD2025
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/KoQ1oUc8s4
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/U3MIokvSsH
In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 receptor agonists. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | NEJM https://t.co/5Hox1DZcLh
Orforglipron, un agonista oral del receptor GLP-1 de moléculas pequeñas para el tratamiento de la obesidad Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/3aXXSmFxgf
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/TCwn2bK6zX
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine?✅ https://t.co/isRidvOoab
νάτο και το χαπάκι! Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/7pi2joNvDu
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 receptor agonists. @NEJM @CMichaelGibson @DrMarthaGulati @hvanspall @lamcardio @AndrewJSauer @dranulala @ankeetbhatt @BiykemB @Drroxmehran @JACCJournals @ACCinTouch https://t.co/5t36x0kt8E
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/qQ9Eu6YFZp #EASD2025
Oral orforglipron over 72 weeks for #weightloss #obesity #EASD2025 www.nejm.org/doi/full/10....
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/kYh2db5YxS
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment https://t.co/6p24qpMKnz
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment: NEJM; 3127 patients; mean change in body weight from baseline to week 72 was −7.5% , −8.2 to −6.8) with 6 mg of orforglipron, −8.4% with 12 mg of orforglipron, −11.2% https://t.co/lYOuJqpnO6
Big randomized trial of a GLP- pill (vs placebo) achieves significant weight loss www.nejm.org/doi/full/10....
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N. Engl. J. Med. 2025, 393, 1796–1806. [Google Scholar] [CrossRef] ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. Sean Wharton; Louis J. Aronne; Adam Stefanski; Nasreen F. Alfaris; Andreea ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. Authors: Sean Wharton, M.D., Louis J. Aronne, M.D., Adam Stefanski, M.D. ...
https://doi.org/10.1016/S0140-6736(25)02165-8 · Google Scholar · Crossref · Search ADS · PubMed. 78. Structure Therapeutics Inc . (. January 2026. ) Structure ...
. 10.1016/S0140-6736(25)02165-8. Pubmed Abstract · CrossRef · Google Scholar; View reference in article. 11. KansakarU.JankauskasS. S.PandeS.MoneP.VarzidehF ...
doi: 10.1016/S0140-6736(25)02165-8. Epub 2025 Nov 20. PMID: 41275875. Kanu C, Kimel M, Clucas C, Goetz I, Neff LM, Boye KS, Karn H. Psychometric Validation ...
DOI: 10.1016/S0140-6736(25)02165-8. pmid: 41275875. Google Scholar. Keywords: Endocrinology; Obesity; Clinical Medicine; Outpatient-Based Clinical Medicine.
Lancet. 2025 Nov 20:S0140-6736(25)02165-8. doi: 10.1016/S0140-6736(25)02165. PubMed Abstract available
https://doi.org/10.1016/S0140-6736(25)02165-8. Hsieh, J., Longuet, C., Baker, C. L., Qin, B., Federico, L. M., Drucker, D. J., &. Adeli, K. (2010). The ...
Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Lancet. 2026 Jan 14:S0140-6736(25) ...
https://doi.org/10.1016/S0140-6736(25)02165-8 Get rights and content. Full text access. Summary. Background. Obesity is a chronic disease that significantly ...
10.1016/S0140-6736(25)02165-8. More actions. Article preview; Recommended articles. Article preview. Abstract; Introduction; Section snippets; References (38) ...
145 views • Jun 25 • 25 min ... doi:10.1016/S0140-6736(26)00656-2 Presented by: • Neil Skolnik, M.D. ...
doi: 10.1016/S0140-6736(25)02165-8 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #diabetes #GLP1 #saludmetabolica ...
https: //doi.org/10.1016/S0140-6736(25)02165-8 • Rosenstock J, et al. N Engl J Med. 2025. ACHIEVE-1. https://doi.org/10.1056/NEJMoa2505669 #Metabolife ...
ORFORGLIPRON: AN ORAL SMALL- MOLECULE GLP-1 RECEPTOR AGONIST FOR OBESITY TREATMENT AUTHORS. LEARNING OBJECTIVES Obesity , classification, management ...
10.1016/S0140-6736(25)02165-8; Lee MM, Sattar N, Pop-Busui R, et al.: Cardiovascular and kidney outcomes and mortality with long-acting ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;393:1796-1806. DOI: 10.1056 ...
Source: Lancet 2026 · PMID 41275875 · doi:10.1016/S0140-6736(25)02165-8. This is the full appraisal — nothing cut. More like it on YouTube ...
https: //doi.org/10.1016/S0140-6736(25)02165-8 • Rosenstock J, et al. N Engl J Med. 2025. ACHIEVE-1. https://doi.org/10.1056/NEJMoa2505669 ...
... Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment." New England Journal of Medicine. 2025. NCT05869903 ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025;393:1796-1806. doi:10.1056 ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. The New England Journal of Medicine, 393(18), 1796–1806 ...
Like. Recent posts. Nuris Arelis González ▻ Medicos. 46w · Public · La obesidad sigue siendo una de las crisis de salud pública más ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment, NEJM — https://www.nejm.org/doi/full/10.1056 ...
The main content is about "Weight Loss & Nutrition" focusing on "Orforglipron, an Oral Small-Molecule GLP -1 Receptor Agonist for Obesity ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine. 2025;393:1796–1806 ...
DOI: 10.1016/S0140-6736(25)02165-8 • Rosenstock J, et al. ACHIEVE-1. New England Journal of Medicine, 2025. DOI: 10.1056/NEJMoa2505669
DOI: 10.1016/S0140-6736(25)02165-8 • Rosenstock J, et al. ACHIEVE-1. New England Journal of Medicine, 2025. DOI: 10.1056/NEJMoa2505669
doi: 10.1016/S0140-6736(25)02165-8 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #diabetes #GLP1 ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025;393:1796-1806. doi:10.1056 ...
Source: Lancet 2026 · PMID 41275875 · doi:10.1016/S0140-6736(25)02165-8. This is the full appraisal — nothing cut. More like it on YouTube ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025;393:1796-1806. doi:10.1056 ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796-1806. doi:10.1056 ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025. doi:10.1056/NEJMoa2511774. @dra ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025 Nov 6;393(18):1796-1806. doi: 10.1056 ...
doi: 10.1016/S0140-6736(25)02165-8 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #diabetes #GLP1 ...
doi:10.1016/S0140-6736(25)02165-8. 4. Welch M, Forst T, Jia W, et al. Orforglipron compared with dapagliflozin in adults with type 2 diabetes ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl. J. Med. 2025, 393(18), 1796–1806. [Google Scholar] ...
The main content is about "Weight Loss & Nutrition" focusing on "Orforglipron, an Oral Small-Molecule GLP -1 Receptor Agonist for Obesity ...
By validating that orforglipron is a small molecule rather than a trad Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for …
ergence of orforglipron—an orforglipron an oral small molecule glp 1 receptor agonist for obesity treatment—marks a departure from traditional ...
Unlike traditional Orforglipron: An Oral Small-Molecule GLP-1 Receptor Agonist for therapies that mimic natural amino acid chains—which are ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment — NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2511774 ...
... 25 Trial Design 0:55 Primary Endpoint 1:20 Safety & Secondary ... DOI: 10.1016/S0140-6736(25)02165-8. PMID: 41275875. Summary for ...
10.1016/S0140-6736(25)02165-8. More actions. Article. Summary. Background. Obesity is a chronic disease that significantly contributes to type 2 ...
... Orforglipron — an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1) Clinical note: Orforglipron is now FDA ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. More about Foundayo (orforglipron). Check interactions ...
No obstante, frente a semaglutida oral se observó una mayor frecuencia de eventos gastrointestinales y suspensiones por efectos adversos, ...
Source: Lancet 2026 · PMID 41275875 · doi:10.1016/S0140-6736(25)02165-8. This is the full appraisal — nothing cut. More like it on YouTube ...
Source: Lancet 2026 · PMID 41275875 · doi:10.1016/S0140-6736(25)02165-8. This is the full appraisal — nothing cut. More like it on YouTube ...
DOI: 10.1016/S0140-6736(25)02165-8 #Orforglipron #fyp #Obesidad ... 10.1016/S0140-6736(25)02165-8 10.1111/dom.15150 10.1097/CRD ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025. ATTAIN-1. • Wharton S, et al. Oral ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025 Nov 6;393(18):1796-1806. doi: 10.1056 ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. The New England journal of medicine, 393(18), 1796–1806 ...
DOI: 10.1016/S0140-6736(25)02165-8; Jastreboff AM, et al. Tirzepatide once weekly for obesity (SURMOUNT-1). N Engl J Med. 2022. PMID ...
7. Horn, D.B. ... Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes ...
18. Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025 Nov 6;393(18):1796-1806. doi: 10.1056 ...
... Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N. Engl. J. Med. 393, 1796–1806 (2025). Article PubMed ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;393(18):1796-1806. doi:10.1056 ...
... 10.1016/S0140-6736(25)02165-8. 7. Chamarthi VS, Daley SF. Special populations and long-term management in obesity medicine. In: StatPearls ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
... Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796-1806. https://pubmed.ncbi ...
https://doi.org/10.1016/S0140-6736(25)02165-8. Iwai S, Kaji K, Nishimura N, et al. Glucagon-Like Peptide-1 Receptor Agonist, Semaglutide ...
S Wharton et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med 2025; 393:1796. doi:10.1056 ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;393(18):1796-806. 4. Horn DB, et al ...
... Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. Published online September 16, 2025. doi ...
... Orforglipron, an oral small-molecule GLp-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796-1806. doi:10.1056 ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025;393:1796-1806. doi:10.1056 ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796-1806. doi:10.1056 ...
... 10.1016/S0140-6736(25)02165-8. PMID: 41275875. Read also: GLP-1RA: Beyond Diabetes, the New Frontier of Medicine · Retatrutide nel diabete ...
; et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): ...
https://doi.org/10.1016/S0140-6736(25)02165-8. Article PubMed Google Scholar. Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, et ...
https://doi.org/10.1016/S0140-6736(25)02165-8; Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults ...
doi:10.1016/S0140-6736(25)02165-8; Lu Y, Chen J, Guo Y, et al. Cardiometabolic Profiles of Oral and Subcutaneous Glucagon-Like Peptide-1 ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025.
OCR: Weight Loss & Nutrition Orforglipron, an Oral Small- Molecule GLP-1 Receptor Agonist for Obesity Treatment IG @SueRay328 Threads ...
The main content is about "Weight Loss & Nutrition" focusing on "Orforglipron, an Oral Small-Molecule GLP -1 Receptor Agonist for Obesity ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;393(18):1796-1806. doi:10.1056 ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. More about orforglipron. Check interactions · Compare ...
Wharton S, Aronne LJ, Stefanski A, et al. ATTAIN-1 Trial Investigators. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025 Nov 6;393(18):1796-1806. doi: 10.1056 ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. The New England journal of medicine, 393(18), 1796–1806 ...
Wharton S, Aronne LJ, Stefanski A, et al. ATTAIN-1 Trial Investigators. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025;393:1796-1806. doi:10.1056/ ...
But many more have trouble affording the costly shots. Study details. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025;393:1796-1806. doi:10.1056 ...
... 10.1016/S0140-6736(25)02165-8 #foundayo #glp1medication #weightloss2026 #noneedles #Orforglipron #weightlossjourney #obesitytreatment ⚕️ ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796-1806. doi:10.1056 ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025 Nov 6;393(18):1796-1806. PMID ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025;393:1796-1806. doi:10.1056 ...
The FDA approved orforglipron, an oral small molecule GLP-1 receptor agonist, for the treatment of obesity and overweight with weight ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment - Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A ...
... 10.1016/S0140-6736(25)02165-8. Newsletter. Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to ...
... Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796-1806. doi:10.1056 ...
... Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796-1806. doi:10.1056 ...
https://doi.org/10.1016/. S0140-6736(25)02165-8. [23] Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, et al. Oral ...
... orforglipron, an oral small-molecule GLP-1 receptor agonist for treating type 2 diabetes and obesity. May be an image of text · ? · ?. Yicai ...
... orforglipron, an oral small-molecule GLP-1 receptor agonist for treating type 2 diabetes and obesity. | Facebook. Log in. Facebook. No photo ...
... orforglipron, an oral small-molecule GLP-1 receptor agonist for treating type 2 diabetes and obesity. May be an image of text · ? · ?. Yicai ...
... orforglipron, an oral small-molecule GLP-1 receptor agonist for treating type 2 diabetes and obesity. No photo description available. Like ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;NEJMoa2511774. Wharton S, Rosenstock J ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796-1806. Available from ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. The New England Journal of Medicine. September 16, 2025 ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025;393:1796-1806. doi:10.1056 ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N. Engl. J. Med. 2025,393, 1796–1806. [CrossRef]. 47 ...
doi: 10.1016/S0140-6736(25)02165-8 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #diabetes #GLP1 ...
Wharton S, Aronne LJ, Stefanski A, et al; ATTAIN-1 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist for ...
[Article] Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. 1 upvote · 2 comments. [Article] Summation and ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
... Sean Wharton et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. NEJM 2025.
[Article] Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. 1. 2. [article]Dynamic control of Na-Cl ...
[Article] Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. 1. 2. [Article]The impact of cannabis and ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. NEJM 2025. An oral GLP-1 shows clinically meaningful ...
... -controlled trial. Lancet. 2025. DOI: 10.1016/S0140-6736(25)02165-8 #Orforglipron #ATTAIN2 #Obesidad #DiabetesTipo2 #GLP1".
DOI: 10.1016/S0140-6736(25)02165-8. Source: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02165-8/abstract. 期刊信息.
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for ...
Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med ...
The Lancet DOI: 10.1016/S0140-6736(25)02165-8. Topics: Diabetes / obesity. Advertisement. Sign up to our weekly newsletter. Receive a weekly ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
DOI: 10.1016/S0140-6736(25)02165-8 External LinkAlso available on ScienceDirect External Link. Copyright: © 2025 Elsevier Ltd. All rights are ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
DOI: 10.1016/S0140-6736(25)02165-8 , www.thelancet.com/journals/lan … (25)02165-8/abstract. Journal information: The Lancet. Key medical ...
https://doi.org/10.1016/S0140-6736(25)02165-8. October Flash SaleFirst Year $10. Enjoy ad-free access to our largest-ever collection of member ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase ...
doi: 10.1016/s0140-6736(25)02165-8. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02165-8/abstract. Currently rated 5.0 ...
https://doi.org/10.1016/. S0140-6736(25)02165-8. See Comment page 2866. *Investigators are listed in the appendix (pp 3–5). Department of ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In patients with #obesity, incretin-based therapies such ...
[Article] Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. 1. 2. [Article] Glucagon-Like Peptide-1 ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment" (https://www.nejm.org/doi/full/10.1056/NEJMoa2511774) ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity November 5, 2025. DOI: 10.1056/NEJMdo008238
Close menu. #more to come #obesity · Orforglipron, an Oral ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
[Article] Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. 1. 2. [ARTICLE] AJM300 (carotegrast methyl), an ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment – NEJM 4. Dementia Risk in People With Type 1 Diabetes and ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
[Article] Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. Requesting. DOI: 10.1056/NEJMoa2511774. URL ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025. doi:10.1056/NEJMoa2511774. ¿Crees que ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. The New England Journal of Medicine. Published online ...
7. Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. Wharton S, Aronne LJ, Stefanski A, et al. The New England ...
New Results from ATTAIN-1 ➝ An Oral Small Molecule GLP-1 Receptor Agonist for Obesity Treatment. Learn more: https://e.lilly/3KoWT4C.
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (Sept 16, 2025) This is an extraordinary achievement for ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine, 2025; DOI: 10.1056 ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
... Study: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
The NEJM just reported impressive weight loss with Orforglipron, the first oral small-molecule GLP-1 receptor agonist. No more injections !
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. https://pubmed.ncbi.nlm.nih.gov/40960239/. (2025 ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine. https://doi.org/10.1056 ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine. doi.org/10.1056 ...
38 likes, 0 comments - shideh_amirifeli on September 17, 2025: "Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine. 2025 Sep 16. DOI ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. Authors: Sean Wharton, M.D., Louis J. Aronne, M.D., Adam ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. Article Publication Date. 16-Sep-2025. COI Statement. See ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
In this phase 3, multinational, randomized, double-blind trial, we examined the safety and efficacy of once-daily orforglipron at doses of 6 ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. The New England Journal of Medicine. Published online ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. The New England Journal of Medicine. Published online ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. The New England Journal of Medicine. Published online ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. The New England Journal of Medicine. Published online ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. The New England Journal of Medicine. Published online ...
Orforglipron approved by FDA for obesity management Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, for Obesity Treatment Sean ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. The New England Journal of Medicine. Published online ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025 Nov 6;393(18):1796-1806. doi: 10.1056 ...
25 DE MAIO - DIA INTERNACIONAL DA TIREOIDE TIREOIDE E GANHO DE ... DOI: 10.1016/S0140-6736(25)02165-8. View all 11 comments · mhelenacris.
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025.
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
DOI: 10.1016/S0140-6736(25)02165-8 • Rosenstock J, et al. ACHIEVE‑1. New England Journal of Medicine, 2025. DOI: 10.1056/NEJMoa2505669
doi: 10.1016/S0140-6736(25)02165-8 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #diabetes #GLP1 ...
10.1016/S0140-6736(25)02165-8; Pillai AA, Sharma AM, Krayem H, Frishman WH, Aronow WS: Orforglipron: A novel oral GLP-1 agonist for the ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796-1806. doi:10.1056 ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
M
ET
N
TL
AM
BM
医ブ
F
SC
AT
PO
LP
D
Y第
LL
Tで
B
UF
A
A
BM
MM
UR
LP
ボ
旅T
AH
DB
NP
DJ
A
L
ER
DM
AM
LC
JM
P
DK
IP
NH
S
AM
S
KD
O
BF
DC
GD
A
DD
FH
MM
JY
A
CP
E
TR
MP
IT
JC
DD
DA
NF
AR
JP
MH
DM
TR
JC
IL
TE
Sシ
KW
DD
AD
DH
AF
DR
KA
D
MT
JM
JR
SX
PF
MR
SP
DB
DG
WM
GP
DA
N
D
GM
NO
BA
EC
S
MT
JA
RG
JQ
HE
DS
SB
DG
J
DS
A
RL
CT
CM
AV
AM
AG
BV
AG
M
V
FL
NA
S
RP
MR
ES
JR
DD
VM
P
SN
M
DC
AO
JA
MA
MH
BS
B
A
MY
C
JA
AV
JC
S
GF
SA
DE
AE
NF
DF
JF
SB
DE
ME
MK
DD
RR
PB